Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | CTSD | P07339 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | DNA2 | P51530 | 1/20 | 0.46 |
| ▸ | CASP6 | P55212 | 1/20 | 0.46 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.46 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.46 |
| ▸ | DTYMK | P23919 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL6223947 | 0.98 | TSHR (0.58) | TSHRTDP1L3MBTL1POLBKDM4E | |
| Ammonia Solution, Strong SCHEMBL2264371 | 0.98 | TSHR (0.58) | TSHRTDP1L3MBTL1POLBKDM4E | |
| SCHEMBL1315874 | 0.89 | TDP1 (0.50) | TSHRTDP1L3MBTL1POLBCTSD | |
| Methane SCHEMBL28307885 | 0.88 | TDP1 (0.49) | TSHRTDP1L3MBTL1POLBCTSD | |
| SCHEMBL15869336 | 0.87 | TDP1 (0.66) | TSHRTDP1L3MBTL1POLBKDM4E | |
| SCHEMBL304456 | 0.87 | TDP1 (0.66) | TSHRTDP1L3MBTL1POLBKDM4E | |
| SCHEMBL29351965 | 0.87 | TDP1 (0.66) | TSHRTDP1L3MBTL1POLBKDM4E | |
| SCHEMBL15741933 | 0.87 | TSHR (0.54) | TSHRTDP1L3MBTL1POLBKDM4E | |
| SCHEMBL282685 | 0.86 | TDP1 (0.60) | TSHRTDP1L3MBTL1POLBKDM4E | |
| SCHEMBL11278116 | 0.86 | TSHR (0.64) | TSHRTDP1L3MBTL1POLBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116087066-B | Sheath liquid for urine analysis and preparation method thereof | 福州汉佰康生物科技有限公司 | 2025-05-16 | — | — | CN | claimed |
| CN-116087066-A | Sheath liquid for urine analysis and preparation method thereof | 福州汉佰康生物科技有限公司 | 2023-05-09 | — | — | CN | claimed |
| CN-116087066-B | Sheath liquid for urine analysis and preparation method thereof | 福州汉佰康生物科技有限公司 | 2025-05-16 | — | — | CN | disclosed |
| CN-116087066-B | Sheath liquid for urine analysis and preparation method thereof | 福州汉佰康生物科技有限公司 | 2025-05-16 | — | — | CN | disclosed |
| US-11733233-B2 | Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases | CELGENE CORPORATION (US) | 2023-08-22 | — | — | US | disclosed |
| CN-116087066-A | Sheath liquid for urine analysis and preparation method thereof | 福州汉佰康生物科技有限公司 | 2023-05-09 | — | — | CN | disclosed |
| CN-116087066-A | Sheath liquid for urine analysis and preparation method thereof | 福州汉佰康生物科技有限公司 | 2023-05-09 | — | — | CN | disclosed |
| US-11419861-B2 | Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases | CELGENE CORPORATION (US) | 2022-08-23 | — | — | US | disclosed |
| CN-114907269-A | Benzimidazole-4-carboxamide derivative with piperazine as connecting group | 南华大学 | 2022-08-16 | — | — | CN | disclosed |
| US-20220003749-A1 | METHODS FOR DETERMINING DRUG EFFICACY FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA, MULTIPLE MYELOMA, AND MYELOID CANCERS | CELGENE CORPORATION (US) | 2022-01-06 | — | — | US | disclosed |
| EP-3077548-B1 | METHODS FOR DETERMINING DRUG EFFICACY FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA, MULTIPLE MYELOMA, AND MYELOID CANCERS | CELGENE CORP (US) | 2021-11-10 | — | — | EP | disclosed |
| US-6310082-B1 | PHARMACEUTICAL COMPOSITION COMPRISING EFFECTIVE POLY(ADP-RIBOSE)POLYMERASE ENZYME INHIBITING AMOUNT OF BENZIMIDAZOLE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT AND/OR PRO-DRUG FORM THEREOF, WITH ACCEPTABLE CARRIER | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 2001-10-30 | — | — | US | disclosed |
| WO-2000064878-A1 | CYCLO-ALKYL SUBSTITUTED BENZIMIDAZOLES AND THEIR USE AS PARP INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2000-11-02 | — | — | WO | disclosed |
| US-6100283-A | PRODRUG PHOSPHATE DERIVATIVE FOR POLY (ADP-RIBOSE) POLYMERASE ENZYME INHIBITOR FOR ADMINISTERING IN CONJUNCTION WITH ANTITUMOR DRUG OR RADIOTHERAPY | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 2000-08-08 | — | — | US | disclosed |
| CN-1195985-A | Benzimidazole compounds | UNIV NEWCASTLE VENTURES LTD (GB) | 1998-10-14 | — | — | CN | disclosed |
| EP-0841924-A1 | BENZIMIDAZOLE COMPOUNDS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1998-05-20 | — | — | EP | disclosed |
| US-5635525-A | DIAGNOSTICS | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-06-03 | — | — | US | disclosed |
| WO-1997004771-A1 | BENZIMIDAZOLE COMPOUNDS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1997-02-13 | — | — | WO | disclosed |
| US-5444068-A | Imidazopyridine derivatives as angiotensin II receptor antagonists, pharmaceuticals, and treatment of hypertension therewith | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-08-22 | — | — | US | disclosed |
| CN-1070646-A | Imidazo-fused iso and heterocycle, their preparation method contains their composition and their application | HOECHST AG (DE) | 1993-04-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11419861-B2 | Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases | CRBN, UBQLN1, UBQLN2 | TSHR 4595/4885TDP1 2037/4885L3MBTL1 1276/4885 |
| US-20220003749-A1 | METHODS FOR DETERMINING DRUG EFFICACY FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA, MULTIPLE MYELOMA, AND MYELOID CANCERS | BCL9, BCL9L, IKZF1 | TSHR 4499/4885TDP1 2470/4885L3MBTL1 1209/4885 |
| US-11733233-B2 | Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases | CRBN, UBQLN1, UBQLN2 | TSHR 4595/4885TDP1 2037/4885L3MBTL1 1276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.